J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
|
|
- Juniper Lambert
- 3 years ago
- Views:
Transcription
1 VOLUME 23 NUMBER 18 JUNE JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d Etude des Lymphomes de l Adulte P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Fermé, B. Christian, E. Lepage, H. Tilly, F. Morschhauser, P. Gaulard, G. Salles, A. Bosly, C. Gisselbrecht, F. Reyes, and B. Coiffier From the Centre Hospitalier Universitaire (CHU) de Brabois, Vandoeuvre les Nancy; Centre Leon Bérard, Lyon; Centre Jean Bernard, Le Mans; Institut Paoli Calmette, Marseille; Institut Gustave Roussy, Villejuif; Hôpital Bon Secours, Metz; CHU Henri Mondor, Créteil; Centre Becquerel, Rouen; CHU de Lille, Lille; Hospices Civils de Lyon, Pierre-Bénite; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Yvoir; and Academisch Ziekenhuis Sint-Jan, Bruges, Belgium. Submitted September 29, 2004; accepted February 10, Authors disclosures of potential conflicts of interest are found at the end of this article. Address reprint requests to Pierre Feugier, MD, Hematology Department, CHU de Brabois, Vandoeuvre les Nancy, France; p.feugier@chu-nancy.fr by American Society of Clinical Oncology X/05/ /$20.00 DOI: /JCO A B S T R A C T Purpose To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma. Patients and Methods LNH98-5 was a randomized study that included 399 previously untreated patients, age 60 to 80 years, with diffuse large B-cell lymphoma. Patients received eight cycles of classical CHOP (cyclophosphamide 750 mg/m 2, doxorubicin 50 mg/m 2, vincristine 1.4 mg/m 2, and prednisone 40 mg/m 2 for 5 days) every 3 weeks. In R-CHOP, rituximab 375 mg/m 2 was administered the same day as CHOP. Survivals were analyzed using the intent-to-treat principle. Results Median follow-up is 5 years at present. Event-free survival, progression-free survival, disease-free survival, and overall survival remain statistically significant in favor of the combination of R-CHOP (P.00002, P.00001, P.00031, and P.0073, respectively, in the log-rank test). Patients with low-risk or high-risk lymphoma according to the age-adjusted International Prognostic Index have longer survivals if treated with the combination. No long-term toxicity appeared to be associated with the R-CHOP combination. Conclusion Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up. This combination should become the standard for treating these patients. J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most frequently diagnosed non-hodgkin s lymphoma (NHL), and more than 50% of these patients are older than 60 years. The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen has been considered the gold standard treatment for patients with DLBCL for more than 25 years. Third-generation regimens, despite their promising initial results, did not prove to be better than the standard CHOP regimen. 1-3 Dose-intense CHOP-like regimens or highdose therapy followed by autologous stem-cell transplantation (ASCT) prolong survivals in high-risk patients but these treatments have an increased toxicity in elderly patients. 4,5 Rituximab (MabThera; Rituxan Roche, Neuilly-sur-Seine, France), is a chimeric human/murine immunoglobulin G1 monoclonal antibody that binds specifically to the 4117
2 Feugier et al B-cell surface antigen, CD20. The antibody induces lymphoma cell lysis through different immunologic or direct mechanisms, complement-mediated cytolysis, antibodydependent cell cytotoxicity, and induction of apoptosis, and acts synergistically with chemotherapy. 6-9 In phase II studies, rituximab has demonstrated efficacy in DLBCL alone and in combination with the CHOP regimen (R- CHOP). 10,11 In 2002, we published the first analysis of the Groupe d Etude des Lymphomes de l Adulte (GELA) Lymphome Non Hodgkinien study 98-5 (LNH98-5) with a 2-year follow-up showing that the addition of rituximab to CHOP chemotherapy significantly increases the rate of complete response (CR), decreases the rates of treatment failure and relapse, and improves event-free survival (EFS) and overall survival (OS) compared with standard CHOP alone in elderly patients with DLBCL. 12 Because the LNH98-5 study was the first study to show a survival benefit of R-CHOP compared with CHOP chemotherapy, extended follow-up is important to determine whether the survival benefit is maintained over time and whether a definitive effect on cure rates can be shown. We report the updated results of the LNH98-5 study with a median follow-up of 5 years. PATIENTS AND METHODS Patients Patients were eligible for enrollment if they were 60 to 80 years old and had previously untreated DLBCL according to the WHO classification. 13 Patients were also required to have stage II, III, or IV disease and performance status 0 to 2 according to the Eastern Cooperative Oncology Group scale. Patients were excluded from the trial if they had T-cell lymphoma; a previous history of indolent lymphoma, CNS or meningeal involvement; a history of active cancer during the previous 5 years; any serious active concomitant disease; or if in the opinion of the investigator, their general status did not allow the administration of eight courses of CHOP. Patients were also excluded from the trial if they had a cardiac contraindication to doxorubicin (abnormal contractility on echocardiography), or a neurologic contraindication to vincristine. Finally, patients with positive serology for HIV or a history of unresolved hepatitis B virus infection (defined by the presence of HBs antigen or HBc antibody without HBs antibody) were not included. Patient enrollment was based on the diagnosis of DLBCL at each study center, but a panel comprising at least three hematopathologists conducted a central pathology review to confirm the diagnosis of CD20-positive DLBCL. Characteristics of the 399 patients included in this study are summarized in Table Staging comprised clinical examination, thoracic and abdominal computed tomography scans, blood counts, measurements of lactate dehydrogenase and beta 2 -microglobulin serum levels, bone marrow biopsy, ECG, echocardiography in patients with a history of cardiac disease or in patients older than 75 years, and CSF examination in patients with bone marrow infiltration or head and neck involvement, or if otherwise clinically indicated. This study complied fully with all provisions of the Declaration of Helsinki and was conducted in accordance with Good Table 1. Baseline Characteristics of the 399 Patients Included in the LNH98-5 Study Comparing CHOP to R-CHOP in Elderly Patients With Diffuse Large B-Cell Lymphoma Characteristic R-CHOP (n 202) No. of Patients % CHOP (n 197) No. of Patients % Age, years Male Performance status Stage.74 I II III IV B symptoms No. of extranodal sites Bulky tumor ( 10 cm) Bone marrow involvement Elevated LDH Age-adjusted IPI score Standard IPI score Abbreviations: LNH98-5, Lymphome Non Hodgkinien study 98-5; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus CHOP; LDH, lactate dehydrogenase; IPI, International Prognostic Index. Clinical Practice rules. All patients gave written informed consent to participate. Random Assignment to Treatment Patients were centrally randomly assigned to treatment with CHOP or R-CHOP after stratification according to center and age-adjusted International Prognostic Index (aaipi) scores (scores 0or1v2or3). 14 Treatment Patients treated with CHOP received cyclophosphamide 750 mg/m 2, doxorubicin 50 mg/m 2, and vincristine 1.4 mg/m 2 up to a maximum dose of 2 mg on day 1, with prednisone 40 mg/m 2 /d on days 1 to 5. Patients were treated every 3 weeks for eight cycles. Patients treated with R-CHOP received rituximab 375 mg/m 2 on day 1 for each of the eight cycles. Rituximab infusion was interrupted in the event of fever, chills, edema, mucosa congestion, hypotension, or any serious adverse event, and it was resumed P 4118 JOURNAL OF CLINICAL ONCOLOGY
3 R-CHOP in Elderly Patients With DLBCL later. No complementary radiation therapy was scheduled either on bulky tumors or on persisting masses at the end of treatment. If a patient developed grade 4 neutropenia or febrile neutropenia after a cycle of CHOP or R-CHOP, all subsequent cycles were administered with granulocyte colony-stimulating factor (G- CSF) support. If new grade 4 neutropenia developed with infection despite of G-CSF support, doses of cyclophosphamide and doxorubicin were decreased by 50% for all following cycles. If grade 4 neutropenia persisted, chemotherapy was discontinued. If a patient developed grade 3 or 4 thrombocytopenia, the doses of cyclophosphamide and doxorubicin were decreased by 50% for all following cycles. If grade 3 or 4 thrombocytopenia persisted, therapy was discontinued. If neutrophils were lower than 1,500/mm 3 or platelets lower than 100,000/mm 3 before a cycle, the cycle was delayed for up to 2 weeks. If the patient s neutrophil and platelet counts did not increase above these levels after 2 weeks, chemotherapy was discontinued. For patients receiving R-CHOP, rituximab was discontinued if CHOP was discontinued. Subsequent treatments for patients withdrawn from CHOP or R-CHOP therapy were administered at the discretion of the investigator. Follow-Up Response to treatment was evaluated after four and eight treatment cycles, or after the planned treatment was discontinued. Thereafter, clinical examination was performed every 3 months for the first 2 years, then every 6 months for the next 3 years, then at the discretion of the investigator. A thoracic and abdominal computed tomography scan was performed after 3 months, then every 6 months during the first 2 years, then annually for 3 more years. Outcome Measures The primary efficacy parameter was EFS. Events were defined as disease progression or relapse, institution of a new (unplanned) anticancer treatment, or death as a result of any cause without progression. Secondary efficacy end points included OS, progression-free survival (PFS), disease-free survival (DFS), response rates, and toxicity. The definition of PFS was almost identical to that of EFS with the exception that late deaths not related to lymphoma or its treatment were not counted as treatment failure. 15 DFS only includes patients who reached a CR or undocumented CR (CRu) at the end of the treatment. EFS, PFS, and OS were calculated as the time from random assignment to the date of the first reported event. DFS was calculated as the time from response assessment to the date of the first reported event. Patients with no reported event at the time of analysis were censored at the most recent assessment date. Tumor responses were classified as CR, CRu, partial response, stable disease, or progressive disease according to the proposed International Workshop criteria. 15 Survival for patients experiencing disease relapse was defined as duration from first day of the new treatment to time of death or last visit. Statistical Analysis Sample size was calculated on the basis of the primary end point or EFS. On the basis of various results obtained in previous studies with CHOP chemotherapy in this patient population, a conservative 3-year EFS rate of 30% was assumed for the CHOP regimen. 1 To detect an increase in the 3-year EFS rate from 30% to 45%, it was calculated that 400 patients recruited during 3 years and observed for a minimum of 1 year would be required to provide 80% power at the overall 5% (.05, two sided) significance level. One patient was not included in the analyses because she withdrew her informed consent. EFS, PFS, DFS, and OS were analyzed using the log-rank test and expressed as Kaplan-Meier plots. Analyses of efficacy and safety included all 399 patients randomly assigned between August 1998 and March 2000 and followed the intent-to-treat principle. Statistical analyses were performed with SAS software (SAS Institute, Cary, NC) by the GELA statistical office. All P values are two tailed. RESULTS Patient Characteristics and Response to Treatment Initial characteristics of the 399 enrolled patients are summarized in Table 1. The median age of the patients at time of inclusion was 69 years. Response rates as previously published were 75% and 63% for CR and CRu, 8% and 6% for incomplete responses (partial response and stable disease), 9% and 22% for progressive disease, and 6% and 6% for death during treatment for patients treated with R-CHOP and CHOP, respectively (P.005). 12 EFS With a median follow-up of 5 years, 248 events have been observed, 106 (52.5% of the patients) in the R-CHOP arm and 142 (72% of the patients) in the CHOP arm (Table 2). Fewer events were observed during treatment in the R-CHOP arm, as reported previously. 12 Over time, more patients experienced disease relapse in the CHOP arm than in the R-CHOP arm (34% v 20%; 2 test, P.0001). More patients died in continuous CR in the R-CHOP arm (8%) compared with the CHOP arm (2.5%; 2 test, P.33). However, many of these patients were elderly and most of the deaths were not related to the lymphoma or its treatment but to concomitant diseases already present before the diagnosis of lymphoma or diseases that appeared subsequently, such as solid tumors. No specific pattern of causes Table 2. No. and Type of Events Observed in Both Arms With a Median Follow-Up of 5 Years Event CHOP No. of Patients % R-CHOP No. of Patients % PD during treatment New treatment PD after SD PD after PR Relapse Death during treatment Death in CR All events No event Total patients Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus CHOP; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response
4 Feugier et al of death was observed in these patients: three deaths were related to lymphoma treatment (Table 3), two deaths were related to severe infections, and one death was related to acute myeloid leukemia, all in R-CHOP patients. Five patients died as a result of secondary cancers (three in the CHOP arm and two in the R-CHOP arm). One and nine cardiovascular-related deaths were observed in CHOP and R-CHOP patients, respectively. At the time of analysis, 96 patients (47.5%) in the R-CHOP arm and 55 patients (28%) in the CHOP arm were in continuous CR. The median EFS was 3.8 years (95% CI, 2.37 to not reached) in R-CHOP patients compared with 1.1 years (95% CI, 0.8 to 1.5) in CHOP patients (P.00002; Fig 1A). The 5-year EFS was 47% (95% CI, 39.9% to 54.1%) in R-CHOP patients compared with 29% (95% CI, 23.1% to 35.8%) in CHOP patients. In addition, a stratified analysis according to aaipi showed the superiority of R-CHOP over CHOP in terms of EFS in low-risk patients (5-year EFS, 63% v 34%; P.00085) as well as in high-risk patients (41% v 27%; P.0037; Fig 2A). PFS PFS is a more accurate end point to describe diseaserelated long-term survival because it does not take into account death in continuous CR not related to lymphoma or its treatment. 15 In this regard, 14 patients in the R-CHOP arm and five in the CHOP arm that were counted as having had treatment failure events in the analysis of EFS died as a result of diseases that were not related to lymphoma or its treatment (Table 3) and were censored for the PFS analysis. Median PFS was not reached (95% CI, 3.4 to not reached) for R-CHOP patients compared with 1 year (95% CI, 0.8 to 1.5) for CHOP patients (P.00001; Fig 1B). The 5-year PFS was 54% (95% CI, 46.8% to 61.1%) in R-CHOP patients compared with 30% (95% CI, 24.4% to 37.3%) in CHOP patients. Stratified analysis according to aaipi showed the superiority of R-CHOP over CHOP in terms of PFS in low-risk patients (5-year PFS, 69% v 34%; P.00013) as well as in high-risk patients (47% v 29%; P.00078; Fig 2B). DFS DFS analyzes the time to relapse in patients who reached a CR or CRu. 15 Patients who died as a result of a non-lymphoma related reason without disease progression were not counted as having had an event. Median DFS was not reached (95% CI, not reached to not reached) for R-CHOP patients compared with 2.45 years (95% CI, 1.49 to not reached) for CHOP patients (P.00031). The 5-year DFS was 66% (95% CI, 56.2% to 74.0%) in R-CHOP patients compared with 45% (95% CI, 36.6% to 55.3%) in CHOP patients. OS Death as a result of any reason occurred in 107 patients after CHOP treatment compared with 85 patients after R-CHOP treatment, and was mostly related to lymphoma Patient Treatment Survival (years) Table 3. Cause of Death for Patients Who Died in Complete Remission Age at Time of Death (years) Cause of Death CHOP Lung cancer CHOP Ovarian cancer CHOP Lung cancer CHOP Infections, neurological attack CHOP Neurological attack, infections R-CHOP Probable cardiac failure R-CHOP Acute myeloid leukemia R-CHOP Unknown, possible cardiac failure R-CHOP Probable cardiac failure R-CHOP Probable cardiac failure R-CHOP Infection, bilateral pneumonia R-CHOP Cardiac attack R-CHOP Gastrointestinal hemorrhage R-CHOP Neurologic attack R-CHOP Suicide R-CHOP Cardiac dysfunction, infections R-CHOP Hepatic failure, ascitis, infections R-CHOP Cardiac failure R-CHOP Infection R-CHOP Renal cancer R-CHOP Probable cardiac failure R-CHOP Probable cardiac failure Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus CHOP. Patient s death considered to be related to lymphoma or its treatment JOURNAL OF CLINICAL ONCOLOGY
5 R-CHOP in Elderly Patients With DLBCL Fig 1. (A) Event-free survival, (B) progression-free survival, and (C) overall survival with a median follow-up of 5 years in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and rituximab plus CHOP (R-CHOP). Log-rank test P values are.00002,.00001, and.0073, respectively. progression. Median OS was not reached (95% CI, not reached to not reached) for R-CHOP patients compared with 3.1 years (95% CI, 2.2 to not reached) for CHOP patients (P.0073; Fig 1C). The 5-year OS was 58% (95% CI, 50.8% to 64.5%) in R-CHOP patients compared with 45% (95% CI, 39.1% to 53.3%) in CHOP patients. Stratified analysis according to aaipi showed the significant superiority of R-CHOP over CHOP in terms of OS in low-risk patients (5-year OS, 80% v 62%; P.023). However, the difference in high-risk patients was only of borderline significance (48% v 39%; P.062; Fig 2C). Progression and Salvage Therapy Of the 399 patients, 202 (50.6%) experienced relapse or progression, including 125 (63%) in the CHOP arm and 77 (38%) in the R-CHOP arm. These patients received different salvage chemotherapy regimens according to each center policy: 14 and three patients were not treated at the time of progression in the CHOP and R-CHOP arms, respectively. Rituximab was not initially available in France and Belgium to treat DLBCL patients who experienced relapse and patients only received standard therapy. Later, rituximab was registered and became available to treat DLBCL: as a result, 22 (20%) of the 109 treated patients in the CHOP arm and nine (12%) of 73 in the R-CHOP arm received rituximab-containing salvage chemotherapy. This explained a difference between the group of patients treated with or without rituximab plus chemotherapy at time of relapse: patients treated without rituximab had a significantly shorter duration of response to CHOP/R-CHOP (P.01). Otherwise the clinical characteristics and response to initial treatment were comparable in both groups. Salvage chemotherapy regimens were mainly dexamethasone, cisplatin, and cytarabine; etoposide, cytarabine, cisplatin, and methylprednisolone; or ifosfamide, carboplatin, and etoposide regimens. Only one patient received autologous transplantation after salvage therapy. The 2-year survival rates of re-treated patients were not statistically different for the two initial randomization arms (26% and 31% in R-CHOP and CHOP arms, respectively;
6 Feugier et al Fig 2. Event-free survival (A), progression-free survival (B), and overall survival (C) with a median follow-up of 5 years of patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab plus CHOP (R-CHOP) according to the age-adjusted International Prognostic Index score at diagnosis: (1) low-risk patients (scores 0 and 1); (2) high-risk patients (scores 2 and 3). All differences are statistically significant except for overall survival in high-risk patients: P values are.00085,.0037,.00013,.00078,.023, and.062, respectively. P.83). However, there was a statistically significant difference for survival if patients received a salvage regimen containing rituximab or not: patients treated with a rituximabcontaining regimen had a 2-year survival of 58% compared with 24% for those treated without rituximab (log-rank test, P.00067; data not shown). Figure 3 shows the survival of these patients according to the randomization groups (CHOP and R-CHOP) and to salvage regimens (with or without rituximab). In the CHOP arm, the benefit of the addition of rituximab at time of salvage therapy is 4122 JOURNAL OF CLINICAL ONCOLOGY
7 R-CHOP in Elderly Patients With DLBCL Fig 3. Effect of rituximab-containing chemotherapy as salvage treatment at time of first progression on overall survival after progression: (A) in patients previously treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; log-rank test, P.00043); (B) in patients previously treated with rituximab plus CHOP (log-rank test, P.076). statistically significant (log-rank test, P.002), whereas it is not statistically significant in the R-CHOP arm (log-rank test, P.23). However, only nine patients received a second regimen with rituximab in the R-CHOP arm. If we only analyzed the 64 patients with duration of response to CHOP/R-CHOP longer than 1 year, patients treated with rituximab have a statistically significantly longer survival than patients treated without rituximab at time of relapse (P.016; median survival not reached compared with 1 year, respectively). Patients who were refractory to chemotherapy (response to CHOP/R-CHOP less than 1 year) did not show a difference in survival according to salvage treatment. Toxicity As previously reported, rituximab did not add toxicity to the CHOP regimen. 12 There was a trend to increased occurrence of infections in all R-CHOP patients after the end of treatment (12 in R-CHOP v six in the CHOP group). Deaths without disease progression were more frequent in R-CHOP patients. No specific pattern of causes of death was observed (Table 3). Nineteen patients have presented a second tumor, 10 in the CHOP group and nine in the R-CHOP group. Two of them might be considered related to treatment: one myelodysplastic syndrome in a CHOP patient and one acute myeloid leukemia in an R-CHOP patient. No pattern was observed for solid tumors, with five lung; three renal; two melanoma and colon; and one each ovarian, prostate, head and neck, cutaneous, and breast cancers. DISCUSSION In this update, we report the long-term results of the first randomized trial with rituximab in combination with chemotherapy in lymphoma, the results of which were published previously with a median follow-up of 2 years. 12 The updated analysis with a median 5-year follow-up confirmed previous results showing a significant prolongation of EFS, PFS, DFS, and OS for patients treated with R-CHOP compared with those treated with CHOP alone. The longer survivals observed in the R-CHOP group is due to lower rates of disease progression during therapy and lower rates of relapse after reaching a CR. Importantly, the EFS, PFS, DFS, and OS curves for R-CHOP and CHOP alone remained separated throughout the follow-up period, indicating that the benefit of combining rituximab with CHOP is durable and translates into an increase in the number of patients who are cured of their lymphoma. After a median follow-up of 5 years, 26% more patients were alive in the R-CHOP arm than in the CHOP arm. Subgroup analysis showed superior EFS and PFS in patients with both high- and low-risk aaipi scores. However, we observed a statistically significant superiority of OS only in low-risk aaipi patients but not in high-risk aaipi patients, mainly due to a higher mortality rate in high-risk patients from diseases unrelated to lymphoma. As our patients became older, we observed more deaths in CR, particularly in patients treated with R-CHOP, even if there was not a statistically significant difference between the two arms. Most of the CHOP patients died after disease progression, whereas R-CHOP patients did not experience disease relapse. As a logical consequence, patients in the latter group died from other, non-lymphoma related diseases. We observed that patients with concomitant diseases or those with poor performance status at the time of diagnosis are more prone to die in CR, a fact that is also observed in the general population. We do not believe that this is related
8 Feugier et al to the treatment received by our patients but rather to the fact that our patients followed a typical natural life history. Since the first publication of our results, several randomized studies testing the addition of rituximab to chemotherapy in different settings have been presented. The Intergroup study (Eastern Cooperative Oncology Group 4494) was more complicated to analyze because of a double randomization, initially between CHOP and R-CHOP, and secondarily for responding patients between no additional treatment and a maintenance treatment with rituximab for 2 years. 16 These patients received half of the rituximab dose administered in our study. Patients treated with R-CHOP seemed to do better than those treated with CHOP only, and rituximab maintenance was mainly effective in patients who did not receive rituximab previously. These results might be interpreted as consistent with our findings but a longer follow-up is certainly necessary to draw any final conclusion. Sehn et al 17 reported a Canadian population-based retrospective analysis comparing outcomes of 294 DLBCL patients treated with a CHOP-like regimen or R-CHOP like regimen. Dose and schedule of rituximab administration were similar to the LNH98-5 study. With a median 2-year follow-up, the authors showed that the addition of rituximab to CHOP has resulted in a dramatic improvement in outcome, both in young and elderly patients. Finally, the MabThera International Trial study showed a similar benefit for the combination of rituximab and CHOP-like chemotherapy in young patients with low- and low-intermediate risk DLBCL. 18 Other studies have been conducted in patients with follicular lymphoma or mantle-cell lymphoma and showed the same benefit for the combination of rituximab plus chemotherapy. 19,20 These data represent a real breakthrough in the treatment of lymphoma patients and suggest that R-CHOP should become the new standard treatment for patients with DLBCL. Adverse events were not increased in patients treated with the combination of rituximab plus chemotherapy compared with chemotherapy alone, suggesting that rituximab is well tolerated. Other studies recently published have confirmed this low toxicity. We did not observe any difference between the incidence of secondary hematologic and nonhematologic cancers in the two regimens. Life-threatening or fatal cardiac events were also similar in both arms of the study. High-dose therapy followed by ASCT is the treatment of choice for patients with relapsed DLBCL who are still responding to salvage therapy. 21,22 However, elderly patients are usually not candidates for ASCT because of age and comorbidity, and a regimen that is easily tolerated yet provides a reasonable response rate may be an attractive alternative to more toxic regimens. Rituximab has been shown to be active both as a single agent and in combination with chemotherapy in relapsed or resistant DLBCL. 10,23,24 An early phase II study evaluating the combination of rituximab with the etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen in 50 heavily pretreated patients showed a response rate of 64%. 25 The EFS and OS at 2 years was 36% and 52%, respectively, with a median EFS and OS of 14 and 29 months, respectively. Our study provides the opportunity to evaluate the rituximab efficacy in patients experiencing relapse who did or did not receive rituximab previously. Although it was not a randomized study, our results support the idea that combined chemotherapy plus rituximab could improve OS when compared with chemotherapy alone in this setting. However, because of the low number of patients re-treated with rituximab, we cannot make a definitive conclusion regarding these patients. Future studies should focus on decreasing the relapse rate without increasing toxicity in these elderly patients. Rituximab administered as maintenance therapy in patients with CR might decrease the relapse rate by increasing the quality of the response. This modality certainly should be tested in a study designed specifically to answer this question, even if the preliminary results of the Intergroup study seem to invalidate this hypothesis. Although difficult to perform in elderly patients, dose intensification of the CHOP regimen by increasing doses or shortening the administration schedule with G-CSF support could be another way to increase the CR rate and to decrease the relapse rate. 5,26,27 Appendix The following persons and institutions participated in this GELA study: Pathologic review committee J. Brière, P. Gaulard, J. Bosq, J.F. Emile, B. Fabiani, and T. Petrella; Statistics E. Lepage and N. Nio; Pharmacist I. Madelaine; GELA clinical research M. Fiore, K. Privat, E. Capellani and all CRA who collected the data; study centers (all in France, unless otherwise specified) Centre Hospitalier Lyon-Sud, Pierre-Bénite B. Coiffier, G. Salles, C. Traullé and C. Thieblemont; Hôpital de Hautepierre, Strasbourg R. Herbrecht; Centre Becquerel, Rouen H. Tilly; Centre Jean Bernard, Le Mans P. Solal-Celigny; Institut Paoli Calmette, Marseilles R. Bouabdallah; Centre Hospitalier Universitaire de Brabois, Nancy P. Lederlin, P. Feugier; Centre Léon Bérard, Lyon C. Sebban; Institut Gustave Roussy, Villejuif J.N. Munck, C. Fermé; Centre Hospitalier de Lens, Lens P. Morel; Hôpital Henri Mondor, Creteil F. Reyes, C. Haioun; Centre Hospitalier de Chambéry, Chambéry M. Blanc; Hôpital Bon Secours, Metz B. Christian; Centre Hospitalier Universitaire de Lille, Lille B. Quesnel; Academisch Ziekenhuis Sint-Jan, Bruges, Belgium A. Van Hoof; Hôpital Saint-Louis, Paris C. Gisselbrecht, N Mounier, P. Brice; Hôpital Purpan, Toulouse M. Attal; Centre Hospitalier Universitaire Dupuytren, Limoges D. Bordessoule; Hôpital Jean 4124 JOURNAL OF CLINICAL ONCOLOGY
9 R-CHOP in Elderly Patients With DLBCL Bernard, Poitiers V. Delwail; Université Catholique de Louvain, Yvoir, Belgium A. Bosly; Centre Hospitalier Universitaire Clemenceau, Caen M. Macro; Centre François Magendie, Pessac G. Marit; Hôpital Pitié Salpétrière, Paris J. Gabarre; Hôpital André Mignot, Le Chesnay S. Castaigne; Centre Hospitalier Universitaire de Nîmes, Nîmes E. Jourdan; Centre Hospitalier de la Durance, Avignon E. Lepeu; Hôpital Pasteur, Colmar B. Audhuy; Centre Antoine Lacassagne, Nice A. Thyss; Clinique Pasteur, Evreux N. Albin; Centre Médical Foch, Suresnes E. Baumelou; Hôtel Dieu, Paris A. Delmer; Centre Hospitalier de Brive, Brive S. Lefort; Centre Hospitalier de Bourg en Bresse, Bourg en Bresse H. Orfeuvre; Hôpital V. Prouvo, Roubaix I. Plantier; Hôpital Bicêtre, Le Kremlin- Bicêtre G. Tertian; Hôpital Necker, Paris B. Varet; Hôpital Beclere, Clamart F. Boué; Centre Hospitalier Universitaire de Dijon, Dijon O. Casasnovas and D. Caillot; Université Catholique de Louvain, Brussels, Belgium E. Van Den Neste; Institut Curie, Paris D. Decaudin; Centre Hospitalier Universitaire Saint-Louis Lariboisière, Paris H. Dombret, J.P. Fermand, and J.M. Zini; Centre Hospitalier Universitaire de Liège, Liège, Belgium G. Fillet; Fondation Drevon, Dijon M. Flesch; Centre Hospitalier R. Dubos, Pontoise Y. Kerneis; Centre Hospitalier d Annecy, Annecy C. Martin; Hôpital de Valence, Valence P.Y. Péaud; Centre Hospitalier de Blois, Blois P. Rodon; Centre Hospitalier Saint-Vincent, Lille C. Rose; Hôtel Dieu, Clermont-Ferrand P. Travade; Clinique Saint-Jean, Lyon B. Velay; Hôpital de Bayonne, Bayonne F. Bauduer; Centre Hospitalier de Libourne, Libourne K. Bouabdallah; Hôpital Emile Muller, Mulhouse J.C. Eisenmann; Hôpital Marc Jacquet, Melun C. Kulekci; Centre Hospitalier Bois de l Abbaye, Seraing, Belgium S. Lampertz; Hôpital Inter Armées Percy, Clamart G. Nedellec; Centre François Baclesse, Caen A.M. Peny; Centre Hospitalier Victor Dupouy, Argenteuil V. Pulik; Hôpital de Chalon, Chalon B. Salles; Centre Hospitalier de Perpignan, Perpignan X. Vallantin; Centre Hospitalier Robert Ballanger, Aulnay sous Bois P. Agranat; Centre Hospitalier Universitaire de Nice, Nice J.P. Cassuto; Centre Hospitalier Hutois, Huy, Belgium J. Collignon; Centre Hospitalier de la Citadelle, Liège, Belgium B. de Prijck; Hôpital Jolimont, Haine Saint Paul, Belgium A. Delannoy; Centre Hospitalier Gilles de Corbeil, Corbeil Essonnes A. Devidas; Hôpital La Fontonne, Antibes J.F. Dor; Hôpital Cochin, Paris F. Dreyfus; Clinique Saint Jean, Brussels, Belgium C. Dubois; Clinique de Chaumont, Chaumont G. Dupont; Centre Val d Aurelle, Montpellier M. Fabbro; Hôpital J. Monod, Le Havre C. Fruchart; Clinique les Fougères, Dieppe J.P. Gaillard; Centre Hospitalier Universitaire de Rennes, Rennes B. Grosbois; Centre René Huguenin, Saint- Cloud M. Janvier; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland N. Ketterer; Centre Hospitalier du Val de Sambre, Sambreville, Belgium C. Leroy; Clinique Saint Pierre, Ottignies, Belgium M. Maerevoet; Hôpital des Canaux, Macon F. Marechal; Hôpital Saint Joseph, Gilly, Belgium P. Mineur; Hôpital Saint Joseph, Arlon, Belgium P. Pierre; Centre Hospitalier Universitaire Nord, Marseille G. Sebahoun; and Centre Hospitalier de Meaux, Meaux C. Soussain. Authors Disclosures of Potential Conflicts of Interest The following authors or their immediate family members have indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. Consultant/Advisory Role: P. Solal-Celigny, Roche; A. Bosly, Roche; C. Gisselbrecht, Baxter, Roche, Schering; B. Coiffier, Genentech, Roche. Honoraria: P. Solal-Celigny, Produits Roche; H. Tilly, Roche; G. Salles, Roche; C. Gisselbrecht, Roche; F. Reyes, Roche; B. Coiffier, Genentech, Roche. Research Funding: A. Bosly, Roche; B. Coiffier, Genentech. For a detailed description of these categories, or for more information about ASCO s conflict of interest policy, please refer to the Author Disclosure Declaration and Disclosures of Potential Conflicts of Interest found in Information for Contributors in the front of each issue. REFERENCES 1. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin s lymphoma. N Engl J Med 328: , Coiffier B: Increasing chemotherapy intensity in aggressive lymphomas: A renewal? J Clin Oncol 21: , Coiffier B: Treatment of aggressive lymphomas, disseminated cases, in Perry MC (ed): 2003 ASCO Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2003, pp Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-hodgkin s lymphoma: Final analysis of the prospective LNH87-2 protocol A Groupe d Etude des Lymphomes de l Adulte Study. J Clin Oncol 18: , Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-hodgkin lymphoma. Blood 102: , Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104: , Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti- CD20 reagents. Blood 103: , Eisenbeis CF, Caligiuri MA, Byrd JC: Rituximab: Converging mechanisms of action in non-hodgkin s lymphoma? Clin Cancer Res 9: , Smith MR: Rituximab (monoclonal anti- CD20 antibody): Mechanisms of action and resistance. Oncogene 22: , Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-cd20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92: , Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-hodgkin s lymphoma. J Clin Oncol 19: , Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med 346: ,
10 Feugier et al 13. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France, International Agency for Research on Cancer, Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive non-hodgkin s lymphoma. N Engl J Med 329: , Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-hodgkin s lymphomas. J Clin Oncol 17: , Habermann TM, Weller EA, Morrison VA, et al: Phase III trial of rituximab-chop (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 102:6a, 2003 (suppl 1) 17. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). Blood 102:29a, 2003 (suppl 1) 18. Pfreundschuh MG, Trümper L, Ma D, et al: Randomized intergroup trial of first line treatment for patients 60 years with diffuse large B-cell non-hodgkin s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti- CD20 antibody rituximab: Early stopping after the first interim analysis. Proc Am Soc Clin Oncol 23:556, 2004 (abstr 6500) 19. Dreyling MH, Forstpointner R, Repp R, et al: Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102:103a, 2003 (suppl 1; abstr 351) 20. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 105: , Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin s lymphoma. N Engl J Med 333: , Shipp MA, Abeloff MD, Antman KH, et al: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin s lymphomas: Report of the jury. J Clin Oncol 17: , Coiffier B: Chemotherapy combined with monoclonal antibodies in the treatment of patients with diffuse large B-cell lymphoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Progress in Oncology Sudbury, MA, Jones & Bartlett, 2005, pp Coiffier B: Effective immunochemotherapy for aggressive non-hodgkin s lymphoma. Semin Oncol 31:7-11, Wilson WH, Gutierrez M, O Connor P, et al: The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47, Coiffier B: Dose intensity or monoclonal antibody in first-line treatment. Hematol J 5:S154-S158, 2004 (suppl 3) 27. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104: , JOURNAL OF CLINICAL ONCOLOGY
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationCHOP PLUS RITUXIMAB VS. CHOP ALONE IN ELDERLY PATIENTS WITH DIFFUSE LARGE-B-CELL LYMPHOMA
PLUS VS. ALONE IN ELDERLY PATIENTS WITH DIFFUSE LARGE-B-CELL LYMPHOMA CHEMOTHERAPY PLUS COMPARED WITH ALONE IN ELDERLY PATIENTS WITH DIFFUSE LARGE-B-CELL LYMPHOMA BERTRAND COIFFIER, M.D., ERIC LEPAGE,
More informationNon-Hodgkin s lymphomas (NHLs) are a
Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationJ Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
More informationDiffuse large B-cell lymphoma: the curable disease?
Hematology Meeting Reports 2007; 1(5):77 86 Diffuse large B-cell lymphoma: the curable disease? Michael Pfreundschuh Med Klinik I, Saarland University Medical School, Homburg/Saar, Germany Corresponding
More informationDavid Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationDE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1
Bone Marrow Transplantation, (1999) 24, 521 526 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Rituximab (anti-cd20 monoclonal antibody) therapy for progressive
More informationJ Clin Oncol 25:787-792. 2007 by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 7 MARCH 1 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Centre Hospitalier Universitaire, Université de Liège, Liège, Belgium; Hôpital Saint-Louis, Assistance
More informationDIFFUSE LARGE B-CELL LYMPHOMA
DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype
More informationRituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy
Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo,
More informationSalvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma
IMAJ VOL 11 January 9 Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma Ariela Dortort Lazar MD 1,, Ofer Shpilberg
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More information1. Introduction. 2. Clinical aspects
1. Introduction MabThera (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen, CD20. This antigen is located on pre-b-
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationMonoclonal Antibody Therapy for Lymphoma: Targeting CD20
Monoclonal Antibody Therapy for Lymphoma: Targeting CD20 Session Chair: Jonathan W. Freidberg, MD Speakers: Michele Ghielmini, MD; Jonathan W. Friedberg, MD; and John P. Leonard, MD Multimodality Therapies
More informationAggressive non-hodgkin s lymphoma long-term survival for all patients?
Hematology Meeting Reports 2007; 1(4):27 41 Aggressive non-hodgkin s lymphoma long-term survival for all patients? Bertrand Coiffier 1 Jacques Tabacof 2 Zhi-Xiang Shen 3 Ulrich Jäger 4 1 Hospices Civils
More informationChemoimmunotherapy resistant follicular lymphoma A single institutional study
Cancer Research Journal 2014; 2(5): 93-97 Published online September 30, 2014 (http://www.sciencepublishinggroup.com/j/crj) doi: 10.11648/j.crj.20140205.13 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online)
More informationSonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
More informationRituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008
Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationMany people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
More informationPhase II Trial of R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients
Original Article Phase II Trial R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients Objective: To determine response and relapse rates in diffuse large B cell lymphoma
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationEffective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationRituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma
Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationJ Clin Oncol 22:4302-4311. 2004 by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 21 NOVEMBER 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin s Lymphoma: A Nationwide
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationRelapsed Diffuse Large B-Cell Lymphoma 10 Years Later
H & 0 C l i n i c a l C a s e S t u d i e s Relapsed Diffuse Large B-Cell Lymphoma 10 Years Later Shikha Jain, MD Neel Shah, MD Stephanie Gregory, MD Rush University Medical Center, Chicago, Illinois Introduction
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationRituximab in non-hodgkin Lymphoma (NHL)
Original Article ISSN: 2070-254X Rituximab in non-hodgkin Lymphoma (NHL) Manal Elhabbash MD 1, Abukris Alwindi MD 2 (1) Assistant Professor, Tripoli University, (2) Medical consultant in oncology & hematology
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationHigh Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience
Yonsei Medical Journal Vol. 47, No. 5, pp. 604-613, 2006 Original Article High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience Hyun Chang,
More informationPerspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on
More informationAgustin Avilés 1, Serafin Delgado 2, Alejandra Talavera 3, Natividad Neri 3, Judith Huerta-Guzmán 3
Eur J Haematol 2002: 68: 144 149 Printed in UK. All rights reserved Copyright # Blackwell Munksgaard 2002 EUROPEAN JOURNAL OF HAEMATOLOGY ISSN 0902-4441 Combined therapy in advanced stages (III and IV)
More informationThe role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.
The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma
More informationSupplementary Online Content
Supplementary Online Content Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving
More informationrituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited
rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationArticles. Funding Groupe d Etudes des Lymphomes de l Adulte and Amgen.
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial Christian Récher,
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationAudience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib
More informationSocial inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
More informationRituximab-Based Chemotherapy and
用 藥 安 全 Drug Safety Rituximab-Based Chemotherapy and Late-Onset Neutropenia Yi-Ling Lu, Wan-Tsui Huang, Chi-Lan Kao, Hsi-Yen Lin Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan Abstract
More informationIn the last decade, passive immunotherapy
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,
More informationRituximab in the Management of Follicular Lymphoma
Hong Kong J Radiol. 2011;14(Suppl):S63-7 REVIEW ARTICLE Rituximab in the Management of Follicular Lymphoma YL Kwong Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong
More informationLymphoma Overview Joseph Leach, MD
Lymphoma Overview Joseph Leach, MD 71 year old male presents with complaints of mild fa5gue and a visible mass in the le: supraclavicular region PE demonstrates a firm easily palpable mass in the le: supraclavicular
More informationAudience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationPREMEDICATIONS: Agent(s) Dose Route Schedule
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationBiogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812
NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationHow I treat patients with diffuse large B-cell lymphoma
How I treat How I treat patients with diffuse large B-cell lymphoma James O. Armitage 1 1 The Joe Shapiro Professor of Medicine, University of Nebraska Medical Center, Omaha Introduction The disease we
More informationSummary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationSTUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan
STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly
More informationHOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1
HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationTITLE: Rituximab for Non-Hodgkin s Lymphoma: A Review of the Clinical and Cost- Effectiveness and Guidelines
TITLE: Rituximab for Non-Hodgkin s Lymphoma: A Review of the Clinical and Cost- Effectiveness and Guidelines DATE: 11 January 2010 CONTEXT AND POLICY ISSUES: Non-Hodgkin s lymphoma is the most common hematological
More information